The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 10, 2021

Filed:

Jun. 27, 2017
Applicant:

Techfields Pharma Co., Ltd., Suzhou Jiangsu, CN;

Inventors:

Chongxi Yu, Plainfield, IL (US);

Lina Xu, Jiangsu, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/04 (2006.01); C07C 271/16 (2006.01); C07C 271/22 (2006.01); C07D 321/12 (2006.01); C07C 219/10 (2006.01); C07C 219/14 (2006.01); C07C 219/28 (2006.01); C07C 229/12 (2006.01); C07C 327/30 (2006.01); C07C 229/58 (2006.01); C07D 455/02 (2006.01); C07C 237/06 (2006.01); C07C 237/20 (2006.01); C07D 207/16 (2006.01); C07K 5/083 (2006.01); C07D 211/62 (2006.01); C07K 5/097 (2006.01); A61K 31/137 (2006.01); C07C 229/36 (2006.01); A61K 31/195 (2006.01); A61K 31/198 (2006.01); A61K 31/277 (2006.01); C07C 317/44 (2006.01); A61K 31/197 (2006.01); A61K 31/24 (2006.01); A61K 31/40 (2006.01); C07C 219/06 (2006.01); C07C 219/32 (2006.01); C07C 237/08 (2006.01); C07C 327/36 (2006.01); C07C 217/60 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/137 (2013.01); A61K 31/195 (2013.01); A61K 31/197 (2013.01); A61K 31/198 (2013.01); A61K 31/24 (2013.01); A61K 31/277 (2013.01); A61K 31/40 (2013.01); C07C 217/60 (2013.01); C07C 219/06 (2013.01); C07C 219/10 (2013.01); C07C 219/14 (2013.01); C07C 219/28 (2013.01); C07C 219/32 (2013.01); C07C 229/12 (2013.01); C07C 229/36 (2013.01); C07C 229/58 (2013.01); C07C 237/06 (2013.01); C07C 237/08 (2013.01); C07C 237/20 (2013.01); C07C 271/16 (2013.01); C07C 271/22 (2013.01); C07C 317/44 (2013.01); C07C 327/30 (2013.01); C07C 327/36 (2013.01); C07D 207/16 (2013.01); C07D 211/62 (2013.01); C07D 321/12 (2013.01); C07D 455/02 (2013.01); C07K 5/0806 (2013.01); C07K 5/0823 (2013.01); C07C 2602/08 (2017.05);
Abstract

One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.


Find Patent Forward Citations

Loading…